Inhibiting WEE1 and IKK-RELA Crosstalk Overcomes TNFα Resistance in Head and Neck Cancers.


Journal

Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042

Informations de publication

Date de publication:
03 06 2022
Historique:
received: 02 08 2021
revised: 20 12 2021
accepted: 10 02 2022
pubmed: 18 2 2022
medline: 7 6 2022
entrez: 17 2 2022
Statut: ppublish

Résumé

TNFα is a key mediator of immune and radiotherapy-induced cytotoxicity, but many cancers, including head and neck squamous cell carcinomas (HNSCC), display TNF resistance due to activation of the canonical IKK-NF-κB/RELA pro-survival pathway. However, toxicities associated with direct targeting of the canonical pathway point to the need to identify mechanism(s) contributing to TNFα resistance and synthetic lethal targets to overcome such resistance in cancer cells. Here, RNAi screening for modulators of TNFα-NF-κB reporter activity and cell survival unexpectedly implicated the WEE1 and CDC2 G2-M checkpoint kinases. The IKKα/β-RELA and WEE1-CDC2 signaling pathways are activated by TNFα and form a complex in cell lines derived from both human papillomavirus (-) and (+) subtypes of HNSCC. WEE1 inhibitor AZD1775 reduced IKK/RELA phosphorylation and the expression of NF-κB-dependent pro-survival proteins Cyclin D1 and BCL2. Combination of TNFα and AZD1775 enhanced caspase-mediated apoptosis in vitro, and combination treatment with radiotherapy and AZD1775 potentiated inhibition of HNSCC tumor xenograft growth in vivo, which could be significantly attenuated by TNFα depletion. These data offer new insight into the interplay between NF-κB signaling and WEE1-mediated regulation of the G2-M cell-cycle checkpoint in HNSCC. Inhibiting WEE1 and IKK-RELA crosstalk could potentially enhance the effects of therapies mediated by TNFα with less systemic immune suppression and toxicity than observed with direct interruption of IKK-NF-κB/RELA signaling.

Identifiants

pubmed: 35176168
pii: 681581
doi: 10.1158/1541-7786.MCR-21-0624
pmc: PMC9177594
mid: NIHMS1782973
doi:

Substances chimiques

Cell Cycle Proteins 0
NF-kappa B 0
RELA protein, human 0
Transcription Factor RelA 0
Tumor Necrosis Factor-alpha 0
Protein-Tyrosine Kinases EC 2.7.10.1
WEE1 protein, human EC 2.7.10.2
I-kappa B Kinase EC 2.7.11.10

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

867-882

Subventions

Organisme : Intramural NIH HHS
ID : Z01 DC000016
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 DC000073
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 DC000074
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA DC000087
Pays : United States

Informations de copyright

©2022 American Association for Cancer Research.

Références

Nat Methods. 2007 Oct;4(10):847-9
pubmed: 17828270
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Cell Cycle. 2013 Oct 1;12(19):3159-64
pubmed: 24013427
Mol Cell. 2019 Aug 22;75(4):669-682.e5
pubmed: 31302002
Clin Cancer Res. 2017 Nov 1;23(21):6541-6554
pubmed: 28790110
Cancer Res. 2018 Aug 15;78(16):4613-4626
pubmed: 29921694
Cancer Res. 2021 May 15;81(10):2666-2678
pubmed: 33414171
Mol Cancer Ther. 2015 Feb;14(2):608-19
pubmed: 25504633
Sci STKE. 2006 Oct 17;2006(357):re13
pubmed: 17047224
Adv Protein Chem Struct Biol. 2017;107:77-115
pubmed: 28215229
Clin Cancer Res. 2015 Nov 1;21(21):4831-44
pubmed: 26124202
Cancer Res Treat. 2022 Jan;54(1):277-293
pubmed: 33971703
Cancer Res. 2016 Sep 15;76(18):5442-5454
pubmed: 27469115
Cell. 1993 Nov 5;75(3):495-505
pubmed: 8221889
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
Cancer. 2017 May 15;123(10):1778-1790
pubmed: 28295222
Proc Natl Acad Sci U S A. 1986 Jul;83(14):5233-7
pubmed: 3487788
Oncogene. 2021 Mar;40(11):2112-2129
pubmed: 33627786
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28287-28296
pubmed: 33093209
J Biol Chem. 1997 Sep 19;272(38):23896-904
pubmed: 9295339
Biochem Soc Trans. 2014 Feb;42(1):76-81
pubmed: 24450631
Cell Rep. 2018 Apr 3;23(1):194-212.e6
pubmed: 29617660
Blood. 2013 Oct 10;122(15):2641-53
pubmed: 23974204
Cancer Discov. 2016 Aug;6(8):914-29
pubmed: 27260156
Proc Natl Acad Sci U S A. 1989 Dec;86(24):10104-7
pubmed: 2602359
Cancer Discov. 2013 Oct;3(10):1108-12
pubmed: 24124232
J Biol Chem. 2005 Dec 30;280(52):43056-63
pubmed: 16260783
Oncogene. 2013 Apr 4;32(14):1854-62
pubmed: 22614018
Cell Rep. 2018 Oct 30;25(5):1332-1345.e5
pubmed: 30380422
Semin Cancer Biol. 2019 Jun;56:12-24
pubmed: 29486318
Clin Cancer Res. 2015 Feb 15;21(4):870-81
pubmed: 25492084
Elife. 2016 May 17;5:
pubmed: 27185527
J Proteome Res. 2015 Jun 5;14(6):2707-13
pubmed: 25873244
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
PLoS Pathog. 2019 Jun 21;15(6):e1007835
pubmed: 31226168
Head Neck. 2007 Oct;29(10):959-71
pubmed: 17405170
Cancer Cell. 2003 May;3(5):421-9
pubmed: 12781359
J Clin Oncol. 2015 Oct 20;33(30):3409-15
pubmed: 25964244
J Biol Chem. 1982 Jun 10;257(11):6064-72
pubmed: 6281254
Nat Genet. 2017 Dec;49(12):1779-1784
pubmed: 29083409
Oncoimmunology. 2018 Jul 23;7(10):e1488359
pubmed: 30288354
Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10389-94
pubmed: 10973490
Head Neck. 2010 Apr;32(4):417-26
pubmed: 19760794
Nucleic Acids Res. 2020 Jul 2;48(W1):W488-W493
pubmed: 32246720
Clin Cancer Res. 2019 Nov 1;25(21):6463-6474
pubmed: 31266830
Cell. 2017 Jul 27;170(3):564-576.e16
pubmed: 28753430
Br J Cancer. 2000 Nov;83(10):1367-74
pubmed: 11044363
Genes Dev. 2004 Dec 1;18(23):2905-15
pubmed: 15545623
Mol Cancer Res. 2019 May;17(5):1115-1128
pubmed: 30679201
Biomolecules. 2015 Aug 18;5(3):1912-37
pubmed: 26295265
Cancers (Basel). 2020 Oct 07;12(10):
pubmed: 33036368
Sci Data. 2014 Sep 30;1:140035
pubmed: 25984343
Clin Cancer Res. 2018 Jun 15;24(12):2740-2748
pubmed: 29535125
Mol Cancer Ther. 2021 Jul;20(7):1257-1269
pubmed: 33947685
J Biol Chem. 1998 Mar 6;273(10):5858-68
pubmed: 9488723

Auteurs

Zhengbo Hu (Z)

Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.
Shaoguan First People's Hospital, Affiliated Hospital of Southern Medical University, Shaoguan, Guangdong, China.

Ramya Viswanathan (R)

Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.

Hui Cheng (H)

Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.

Jianghong Chen (J)

Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.

Xinping Yang (X)

Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.

Angel Huynh (A)

Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.

Paul Clavijo (P)

Translational Tumor Immunology Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.

Yi An (Y)

Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.

Yvette Robbins (Y)

Translational Tumor Immunology Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.

Christopher Silvin (C)

Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.

Clint Allen (C)

Translational Tumor Immunology Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.

Pinar Ormanoglu (P)

RNAi Screening Facility, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland.

Scott Martin (S)

RNAi Screening Facility, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland.

Shaleeka Cornelius (S)

Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.

Anthony Saleh (A)

Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.

Zhong Chen (Z)

Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.

Carter Van Waes (C)

Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.

Ethan L Morgan (EL)

Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH